Navigation Links
Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms*
Date:3/15/2010

e number of hot flashes. In many of these studies, the benefits of those products were statistically insignificant.''

Mechanism of Action

The mechanism of action of ERr 731 in Estrovera may be attributed to the presence of hydroxystilbenes, a type of phytoestrogen that acts as a selective estrogen receptor modulator, or SERM, and which can be found in high concentrations in Siberian rhubarb. SERMs are compounds that may deliver the benefits of estrogen without its side effects.

Menopause: A Natural Progression

Menopause is part of the natural progression of a woman’s life. But for up to 8 out of 10 women, this time of transition -- which can last anywhere from 2 to 10 years -- can be fraught with an array of climacteric symptoms that can negatively affect their quality of life. Most bothersome of these complaints are hot flashes and “night” sweats, two vasomotor symptoms that can occur any time of the day. These symptoms can leave a woman feeling uncomfortable and embarrassed and cause her to awaken frequently at night, leading to exhaustion, mental fatigue, and depression. During the early stages of menopause, called perimenopause, these symptoms can be especially frequent and intense; some perimenopausal women experience 10 or more moderate to severe hot flashes in a single day.

''We’re excited to be able to bring Estrovera and its key ingredient ERr 731 to the North American market,'' said Bland. “Women’s health specialists and their patients are looking for safe, natural, and effective approaches to address menopausal symptoms. Estrovera provides that option.*”

Estrovera is the newest addition to Metagenics’ full line of high quality, science-based nutraceuticals formulated to address the health needs of women at every stage of life. Estrovera is only available through authorized Metagenics practitioners. For more information please visit

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. Nordic Naturals, Carlson Laboratories and Metagenics Announce Dismissal of Patent Infringement and Unfair Competition Suit
2. Alticor Enters Into Joint Venture Agreement With Metagenics
3. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
4. UPMC Health Plan Launches New Personal Health Record
5. HealthInsuranceFinders.com Launches Video Contest for Young Directors
6. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms*
(Date:9/1/2014)... September 02, 2014 Renal cell carcinoma (RCC) ... lining of the proximal convoluted tubule, a part of the ... from the blood to the urine. The condition is asymptomatic ... RCC are often in the advanced stages of the disease ... RCC often include blood in the urine, flank pain, a ...
(Date:9/1/2014)... London, UK (PRWEB) September 01, 2014 ... in developing more effective treatments for Alzheimer's disease ... disease. Uncertainties also exist regarding the diagnosis of ... hence, the lack of appropriate diagnostic tests. ... range of the greatest breakthroughs in the medicine ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... September 01, 2014 BCC Research ( ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the global ... in 2013 and is expected to reach $38.7 million ... $471.5 million by 2019, which is equivalent to 64.9% ... The receptor-mediated transport (RMT) segment is forecasted to grow ...
(Date:9/1/2014)... September 01, 2014 Top10BestSEOHosting.com has ... many web host suppliers carefully, Top10BestSEOHosting.com is here ... the best web hosting suppliers in 2014. , ... clients with a top-of-the-line shared hosting plan. The ... easy-to-use platform that is affordable, accessible and powerful ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... Recent surveys from,Centers for Disease Control and ... Epidemiology (APIC) have raised awareness of the,threat ... Staphylococcus aureus (MRSA). As the public learns,more ... simple steps,to protect themselves and loved ones ...
... NGSX ), a biopharmaceutical company focused on developing ... results for its third quarter of 2007 on Wednesday, ... call to review the results will begin at 4:30 ... will be hosted by Anthony DiTonno,President and Chief Executive ...
... overwhelming majority, 90 percent of Americans, claim a particular ... religiously diverse than ever before, which is why it ... clients beliefs stem from, says Dr. E. Thomas Dowd, ... much less religious than the general population, says Dowd. ...
... Commonwealth University researchers have discovered a new mechanism to ... clotting disorders, which could lead to novel therapies to ... in the body in areas such as the legs. ... a protein involved in coagulation, is inhibited, rendering blood ...
... - Request Provides CMS with New Scientific ... Ortho Biotech Products, L.P.,the company that ... that the Centers for Medicare and Medicaid ... (NCD) for,erythropoiesis-stimulating agents (ESAs). The company,s request ...
... the Washington,state man who,s spent more than a year walking ... to conclude his odyssey,today at the southernmost city in the ... Gregory set out from his home near the Canadian,border in ... job,with a beverage distributor to accommodate his plans. His trek ...
Cached Medicine News:Health News:Six Simple Steps to Protect Against and Stop the Spread of Superbugs 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 2Health News:NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007 3Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 2Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 3Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 4Health News:Ortho Biotech to Submit Official Request for Reconsideration to CMS Regarding ESA Coverage Policy 5Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... YORK , July 7 Reportlinker.com announces that a new market research ... , Stakeholder ... , , , ... , , ...
... July 7 Scientists have used a genetically reprogrammed herpes virus ... metastatic disease in mice – still an elusive goal when treating humans ... Gene Therapy. , ... Less than 30 percent of patients with metastatic cancer survive ...
Cached Medicine Technology:Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 2Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 3Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 4Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 5Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 6Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 7Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 8Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 9Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 10Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 11Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 12Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 13Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina 14Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 2Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 3Reprogrammed Herpes Virus Given Systemically Before Anti-vascular Drug Shrinks Distant Sarcomas 4
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
... The BacT/Alert 3D Select is ... automated microbial detection system that ... and mycobacteria culturing. This system ... management or laboratory information system ...
Medicine Products: